MA39942A - Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers - Google Patents

Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Info

Publication number
MA39942A
MA39942A MA039942A MA39942A MA39942A MA 39942 A MA39942 A MA 39942A MA 039942 A MA039942 A MA 039942A MA 39942 A MA39942 A MA 39942A MA 39942 A MA39942 A MA 39942A
Authority
MA
Morocco
Prior art keywords
radiotherapy
treatment
positive cancers
combination
immuno therapy
Prior art date
Application number
MA039942A
Other languages
French (fr)
Inventor
Nicola Mason
Yvonne Paterson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/en
Priority claimed from US14/669,629 external-priority patent/US10016617B2/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA39942A publication Critical patent/MA39942A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention provides methods for inducing an immune response against a her-2/neu antigen-expressing tumor and for treating the same and vaccinating against the same in human and canine subjects using a combination of radiation therapy and a recombinant attenuated
MA039942A 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers MA39942A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers

Publications (1)

Publication Number Publication Date
MA39942A true MA39942A (en) 2017-03-08

Family

ID=54359144

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039942A MA39942A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Country Status (11)

Country Link
EP (1) EP3137107A4 (en)
JP (1) JP2017514904A (en)
KR (1) KR20170002552A (en)
CN (1) CN106794234A (en)
AU (1) AU2015253737A1 (en)
CA (1) CA2947677A1 (en)
IL (1) IL248704A0 (en)
MA (1) MA39942A (en)
MX (1) MX2016014367A (en)
SG (1) SG11201609135VA (en)
WO (1) WO2015167748A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
KR20140134695A (en) 2012-03-12 2014-11-24 어드박시스, 인크. Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (en) 2014-02-18 2016-11-14 어드박시스, 인크. Biomarker directed multi-target immunotherapy
BR112016024352A2 (en) 2014-04-24 2018-01-23 Advaxis, Inc. "recombinant listeria strain, recombinant listeria, pharmaceutical composition, and methods of inducing an immune response against a tumor or cancer in a human and listeria individual"
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
EP3464560A4 (en) * 2016-06-03 2020-01-15 Etubics Corporation Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
MX2020003100A (en) 2017-09-19 2020-08-20 Advaxis Inc COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR <i>LISTERIA </i>STRAINS.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
KR20060130038A (en) * 2003-10-15 2006-12-18 메디뮨 인코포레이티드 Listeria-based epha2 vaccines
US9084747B2 (en) * 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
WO2011149852A1 (en) * 2010-05-23 2011-12-01 Aduro Biotech Methods and compositions using listeria for adjuvant treatment of cancer

Also Published As

Publication number Publication date
AU2015253737A1 (en) 2016-12-22
CN106794234A (en) 2017-05-31
KR20170002552A (en) 2017-01-06
MX2016014367A (en) 2017-06-30
EP3137107A1 (en) 2017-03-08
IL248704A0 (en) 2017-01-31
JP2017514904A (en) 2017-06-08
SG11201609135VA (en) 2016-11-29
CA2947677A1 (en) 2015-11-05
WO2015167748A1 (en) 2015-11-05
EP3137107A4 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
MA39942A (en) Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
IL280707A (en) Diagnostic and therapeutic methods for the treatment of breast cancer
IL261008B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
BR112018013731A2 (en) anti-egfr combinations for tumor treatment
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
IL272740A (en) Combination immune therapy and cytokine control therapy for cancer treatment
MX2019011148A (en) Treatment methods.
BR112018013733A2 (en) anti-cd20 combinations for the treatment of tumors
MX2017005258A (en) Combination therapy for treatment of disease.
MX2016011114A (en) Compositions and methods for the treatment of her2/neu over-expressing tumors.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018001755A (en) Smallpox vaccine for use in cancer treatment.
MX2019003722A (en) Tert immunogenic compositions and methods of treatment using the same.
FI3773689T3 (en) Antigenic peptides for prevention and treatment of cancer
MX2019008233A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy.
IL279591A (en) Methods of treating cancer using combination therapy
IL281845A (en) Combination therapy for the treatment of cancer
IL281439A (en) Combination therapy for treating blood cancer
IL284162A (en) Combination therapy for the treatment of cancer
IL279277A (en) In vivo controlled combination therapy for treatment of cancer
IL276068A (en) Iort device for radiotherapy treatment of cancer patients
EP4037761C0 (en) Device for radiotherapy treatment of cancer patients
IL275913A (en) Methods and combination therapy to treat cancer
MX2021001288A (en) Vaccination with microvesicles derived from tumour cells for cancer treatment.